Some of our Uniphar team are attending Reuters Events Pharma today in Barcelona. Stop by and see us at stand #24.
We were delighted to witness such an enthusiastic and captivated audience with Head of Consulting, Nick Bartlett, earlier today - who draws quite the crowd with his positive energy at Reuters Events Pharma. #REpharma #Uniphar
Head_Talent, Leadership & OD | Strategic HR | Digital Learning Strategist | Coach & Facilitator I Digital Transformation I Change Management | Sales Training & Enablement | Human Capital Development
"Is/Are the drug/s you are consuming Saving the Life or Disrupting the Life?" "What if the next blockbuster drug came at the cost of your conscience?" This provocative question lies at the heart of 'Pill', the gripping web series that's got the pharmaceutical world talking. For every Indian pharma professional, this show is more than entertainment. Here's why 'Pill' is a must-watch: Insider's Perspective: Get a rare glimpse into the intricate world of drug development and pharma business dynamics. Ethical Dilemmas: Explore moral challenges that resonate with Phama world situations faced in the industry. Regulatory insights: Witness a dramatized but informative view of the complex regulatory landscape Pharma navigate. Industry dynamics: Experience the high-stakes competition and pressure that define Pharma field. Public perception: Gain valuable insights into how outsiders view Pharma industry. Have you watched 'Pill'? #Pharma #Webseries #IndianPharma
We're excited to share insightful conversations with industry leaders in our latest edition. 🚀 Here’s an engaging interview with Mr. Mannan Khambati, Assistant Vice President Biotech at Bharat Serums and Vaccines Limited, discussing the importance of integrity in the pharma industry. 🔍 Want to know more about what top leaders think about the current trends and challenges in pharma? 📖 Dive into our magazine for more such engaging interviews and industry insights. Don’t miss out! Grab your copy now https://lnkd.in/dyeEk5WH and join the conversation. #pharmanowjulyedition #pharmaleadership #integrityinpharma #pharmainsights
Do pharmaceutical companies unfairly bilk American patients when they charge exorbitant prices for drugs developed based on publicly funded research? In a hearing of the House Committee on Oversight and Reform in January 2019, U.S. Representative Alexandria Ocasio-Cortez of New York argued that “the public is acting as early investor, putting tons of money into the development of drugs that then become privatized, and then they receive no return on the investment that they have made”. Embedded in this “pay twice” argument are three key questions. First, to what extent is public funding responsible for the invention of most new drugs? Second, are U.S. taxpayers inadequately rewarded for their contribution to new drug development? And third, how are these claims salient to the national debate over drug prices? while around the world the same medications cost a fraction of the prices Americans are paying highest prices. Soaring drug prices in America have left many Americans unable to pay for medications and treatments that could otherwise improve their health and well-being. 58 million Americans experience medication insecurity, or the inability to pay for a medication in the last 12 months, according to a Gallup report published by Senator Chuck Grassley. “How many die as a result of that? How many suffer unnecessarily? Nobody knows. But my guess, it is in the millions,” said Senator Bernie Sanders at a recent hearing on the topic of high drug costs, according to reports from Medpage Today. Drug prices in America remain significantly higher than any other wealthy country. In 2018, drug prices were nearly double those in Britain and France even after accounting for discounts American consumers use, according to research from the RAND Corporation. As an example, consider insulin, a drug that helps lower blood sugar levels in diabetics. A vial of insulin costs on average about $99 in the United States, which is 4.7 times more expensive than the same vial of insulin in the second most expensive country Chile, which prices it at nearly $21 according to reports from RAND Corporation. A more dramatic example would be the pricing of the oral pill that can cure Hepatitis C. The list price for a monthly supply is over $13,000 in America, but less than $200 in Ethiopia, according to the International Journal of Health Policy and Management.
The #BioVerse EP007 Webinar - "Leverage Commercial Lens to Enable Effective Drug Development and Success" has concluded with a highly engaging and productive discussion. Led by a panel of experienced industry veterans, including Hui Huang, Christina J. Ansted, MPH, CCMEP, and Jiamin Zhuo. The session explored the critical, yet frequently neglected, facet of #commercial #strategy within drug development. It emphasized that commercialization transcends mere marketing at the launch phase, representing an integrated process initiated as early as the preclinical stages. Participants shared commercial insights and business development experiences, enriched with behind-the-scenes anecdotes. They specifically advised #emerging #biotech companies, including those in #China, to adopt a commercial mindset to enhance asset-building and foster partnership development. The Importance of #Early #Commercial #Planning The discussion also illuminated common misconceptions and strategic pitfalls, such as underestimating the impact of early-stage decisions on later commercial success. For example, choice of indication, dosing strategy, and comparator selection in clinical trials can significantly influence a drug's value proposition. The discussion highlighted Selexys Pharmaceuticals' strategic shift from the crowded asthma market to the niche of sickle cell pain crisis management. This move attracted investors to its anti-P-selectin mAb, resulting in a $660 million Novartis acquisition after Phase 2 success, underscoring the importance of early commercial planning. This case highlights the indispensable role of meticulous commercial planning from the outset. #Proactive #Engagement with Key Stakeholders A significant emphasis was placed on the importance of initiating payer/KOL engagement early. This strategy is instrumental in cultivating robust relationships with key stakeholders, while also securing insights that are pivotal for shaping clinical development and market access strategies. Such proactive engagement positions companies not merely as participants in a standard procedure but as #allies committed to addressing unmet needs. This perspective can significantly set you apart from competitors, offering a distinct advantage in the marketplace. Leveraging Commercial Insights for #Business #Development The panelists also explored the practical aspects of leveraging commercial insights for BD activities. A well-articulated commercial plan can enhance the attractiveness of an asset to potential partners and investors by demonstrating a clear understanding of the market landscape, competitive differentiation, and value drivers. This understanding, with solid evidence, can substantiate the asset's value proposition and establish trust with potential partners, leading to more favorable deal terms. Revisit the episode by clicking here: https://lnkd.in/eB8iv7Hr
It was a privilege to dialogue with Hui Huang and Christina J. Ansted, MPH, CCMEP, during the #BioVerse #Webinar, which focused on the crucial importance of integrating commercial considerations into #drug #development and #business #development processes. This webinar garnered the attention of over #17K live attendees, underscoring the pressing demand for a deeper comprehension of the often underappreciated aspect of #commercial #strategy. Such insights could empower companies to refine their development strategies and enhance their ability to attract investments/strategic partnerships. https://lnkd.in/eQgdTipW
The #BioVerse EP007 Webinar - "Leverage Commercial Lens to Enable Effective Drug Development and Success" has concluded with a highly engaging and productive discussion. Led by a panel of experienced industry veterans, including Hui Huang, Christina J. Ansted, MPH, CCMEP, and Jiamin Zhuo. The session explored the critical, yet frequently neglected, facet of #commercial #strategy within drug development. It emphasized that commercialization transcends mere marketing at the launch phase, representing an integrated process initiated as early as the preclinical stages. Participants shared commercial insights and business development experiences, enriched with behind-the-scenes anecdotes. They specifically advised #emerging #biotech companies, including those in #China, to adopt a commercial mindset to enhance asset-building and foster partnership development. The Importance of #Early #Commercial #Planning The discussion also illuminated common misconceptions and strategic pitfalls, such as underestimating the impact of early-stage decisions on later commercial success. For example, choice of indication, dosing strategy, and comparator selection in clinical trials can significantly influence a drug's value proposition. The discussion highlighted Selexys Pharmaceuticals' strategic shift from the crowded asthma market to the niche of sickle cell pain crisis management. This move attracted investors to its anti-P-selectin mAb, resulting in a $660 million Novartis acquisition after Phase 2 success, underscoring the importance of early commercial planning. This case highlights the indispensable role of meticulous commercial planning from the outset. #Proactive #Engagement with Key Stakeholders A significant emphasis was placed on the importance of initiating payer/KOL engagement early. This strategy is instrumental in cultivating robust relationships with key stakeholders, while also securing insights that are pivotal for shaping clinical development and market access strategies. Such proactive engagement positions companies not merely as participants in a standard procedure but as #allies committed to addressing unmet needs. This perspective can significantly set you apart from competitors, offering a distinct advantage in the marketplace. Leveraging Commercial Insights for #Business #Development The panelists also explored the practical aspects of leveraging commercial insights for BD activities. A well-articulated commercial plan can enhance the attractiveness of an asset to potential partners and investors by demonstrating a clear understanding of the market landscape, competitive differentiation, and value drivers. This understanding, with solid evidence, can substantiate the asset's value proposition and establish trust with potential partners, leading to more favorable deal terms. Revisit the episode by clicking here: https://lnkd.in/eB8iv7Hr
Your CDMO delivering solutions | Business Developer | Striving for excellence every day 🌟
Do you want to avoid delays during your Drug Development journey? Are the necessary steps covered and assessed? Can you reconcile flexibility and planning? We all know the hard truth: out of more than 10,000 drugs in development only a few will reach commercialisation. Let's go through 7 golden rules that Recipharm put together to help you navigate through the hurdles of Drug Development. Highlights: ⏩ Necessary questions to answer for a good start ⏩ How to plan and collaborate ⏩ How a good execution can ensure flexibility and time saving https://lnkd.in/ewvvv7bJ
To watch the full video, Tap the link given below https://bit.ly/4aFHLIF 🔍 Curious about the prowess of Indian Pharma Companies? 🌐🏥 Dive into Part 1 of our series "Indian Pharma Companies at Par with MNCs!" 🇮🇳🌐 Explore the journey from miracles to 1984, where 2 Indian companies stand strong among 25 MNCs. 🚀💊 Stay tuned for insights and revelations! 🎥✨ #pharmaInsights #careerguidance #industryperspective #pharmajeeto #kareersity #guidance #careeradvice #pharmaindustry
Check the summary of #Bioverse Episode 7 moderated by our own Jiamin Zhuo.
The #BioVerse EP007 Webinar - "Leverage Commercial Lens to Enable Effective Drug Development and Success" has concluded with a highly engaging and productive discussion. Led by a panel of experienced industry veterans, including Hui Huang, Christina J. Ansted, MPH, CCMEP, and Jiamin Zhuo. The session explored the critical, yet frequently neglected, facet of #commercial #strategy within drug development. It emphasized that commercialization transcends mere marketing at the launch phase, representing an integrated process initiated as early as the preclinical stages. Participants shared commercial insights and business development experiences, enriched with behind-the-scenes anecdotes. They specifically advised #emerging #biotech companies, including those in #China, to adopt a commercial mindset to enhance asset-building and foster partnership development. The Importance of #Early #Commercial #Planning The discussion also illuminated common misconceptions and strategic pitfalls, such as underestimating the impact of early-stage decisions on later commercial success. For example, choice of indication, dosing strategy, and comparator selection in clinical trials can significantly influence a drug's value proposition. The discussion highlighted Selexys Pharmaceuticals' strategic shift from the crowded asthma market to the niche of sickle cell pain crisis management. This move attracted investors to its anti-P-selectin mAb, resulting in a $660 million Novartis acquisition after Phase 2 success, underscoring the importance of early commercial planning. This case highlights the indispensable role of meticulous commercial planning from the outset. #Proactive #Engagement with Key Stakeholders A significant emphasis was placed on the importance of initiating payer/KOL engagement early. This strategy is instrumental in cultivating robust relationships with key stakeholders, while also securing insights that are pivotal for shaping clinical development and market access strategies. Such proactive engagement positions companies not merely as participants in a standard procedure but as #allies committed to addressing unmet needs. This perspective can significantly set you apart from competitors, offering a distinct advantage in the marketplace. Leveraging Commercial Insights for #Business #Development The panelists also explored the practical aspects of leveraging commercial insights for BD activities. A well-articulated commercial plan can enhance the attractiveness of an asset to potential partners and investors by demonstrating a clear understanding of the market landscape, competitive differentiation, and value drivers. This understanding, with solid evidence, can substantiate the asset's value proposition and establish trust with potential partners, leading to more favorable deal terms. Revisit the episode by clicking here: https://lnkd.in/eB8iv7Hr
In our latest #blog, Dr. Richard Castledine, Head of Drug Substance Operations, outlines key takeaways from our recent webinar on the crucial steps drug developers must consider in regard to the evolving landscape of #psychedelic drug development. To read: https://bit.ly/3ARqdMf
Consultative Development Manager Parexel Biotech at Parexel #neverstopbioteching #clinicaltrials #patientsfirst #globalexpertise
In the latest episode of the Parexel podcast series, "De-Risking Drug Development," our host, Paul Bridges, and colleagues discuss the challenges and critical decision points in early-phase clinical development. Join Mwango Kashoki, Camilla Ramdeen, and Oliver Fuhrmann as they delve into the reasons why a third of drugs fail to progress from phase two, the role of feasibility planning in patient selection, and the potential of #AI in making studies more efficient and attractive. This multi-perspective discussion ends with each of our speakers sharing one key takeaway that biotech leaders should, but often don't, consider at this phase of their drug development. Don't get stuck in phase one. Learn how we're mitigating risk for biotech companies. #ParexelBiotech #EarlyPhase #ClinicalDevelopment #Biotech
